|
|
|
Volumn 47, Issue RR-17, 1998, Pages 1-14
|
|
Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement. Centers for Disease Control and Prevention.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ZIDOVUDINE;
ANIMAL;
ANTIBIOTIC RESISTANCE;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
DRUG EFFECT;
ECONOMICS;
EVALUATION;
HIGH RISK BEHAVIOR;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
REVIEW;
RISK;
SEXUAL BEHAVIOR;
SUBSTANCE ABUSE;
ANIMALS;
ANTI-HIV AGENTS;
CLINICAL TRIALS;
COST-BENEFIT ANALYSIS;
DRUG RESISTANCE, MICROBIAL;
EVALUATION STUDIES;
HIV;
HIV INFECTIONS;
HUMANS;
RISK;
RISK-TAKING;
SEXUAL BEHAVIOR;
SUBSTANCE ABUSE, INTRAVENOUS;
ZIDOVUDINE;
|
|
EID: 0032566466
PISSN: 10575987
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (109)
|
|
References (56)
|